Related Experiment Video
Updated: Apr 21, 2026
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
Chimeric adeno-associated virus and bacteriophage: a potential targeted gene therapy vector for malignant glioma
Paladd Asavarut1, Kevin O'Neill, Nelofer Syed
1Phage Therapy Group, Department of Medicine, Imperial College London, Burlington Danes Building, Hammersmith Hospital, Du Cane Road, London, UK.
Abstract:
The incipient development of gene therapy for cancer has fuelled its progression from bench to bedside in mere decades. Of all malignancies that exist, gliomas are the largest class of brain tumors, and are renowned for their aggressiveness and resistance to therapy. In order for gene therapy to achieve clinical success, a multitude of barriers ranging from glioma tumor physiology to vector biology must be overcome. Many viral gene delivery systems have been subjected to clinical investigation; however, with highly limited success. In this review, the current progress and challenges of gene therapy for malignant glioma are discussed. Moreover, we highlight the hybrid adeno-associated virus and bacteriophage vector as a potential candidate for targeted gene delivery to brain tumors.
Insights
Gene therapy for aggressive brain tumors like malignant glioma shows promise but faces significant challenges. A novel hybrid vector combining adeno-associated virus and bacteriophage may improve targeted gene delivery.
Area of Science:
- Oncology
- Gene Therapy
- Neuroscience
Background:
- Malignant gliomas are aggressive brain tumors known for therapeutic resistance.
- Gene therapy has progressed rapidly but faces hurdles in clinical application for brain cancers.
- Current viral gene delivery systems have shown limited success in treating gliomas.
Purpose of the Study:
- To review the current progress and challenges of gene therapy for malignant glioma.
- To identify potential solutions for overcoming barriers in glioma gene therapy.
- To highlight a novel vector for targeted gene delivery to brain tumors.
Main Methods:
- Literature review of gene therapy strategies for malignant glioma.
- Analysis of challenges including tumor physiology and vector biology.
- Evaluation of viral gene delivery systems and novel vector approaches.
Main Results:
- Gene therapy for cancer, including gliomas, is advancing from research to clinical settings.
- Significant barriers related to glioma biology and vector systems impede clinical success.
- Viral vectors have demonstrated limited efficacy in clinical investigations for glioma treatment.
Conclusions:
- Overcoming barriers in gene therapy for malignant glioma is crucial for clinical success.
- A hybrid adeno-associated virus and bacteriophage vector is proposed as a promising candidate.
- This novel vector may enable targeted gene delivery for improved brain tumor treatment.
